ClinicalTrials.gg
CompletedNCT02631538Updated Jun 9, 2021Results posted

Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome

A Phase 2 interventional study of Belimumab and Rituximab in Sjogren's Syndrome, sponsored by GlaxoSmithKline. Completed at 36 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-09.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies in Sjogren's Syndrome with a site in France — 18 open to participants now, 25 under way, 7 of them phase 3. Sjogren's Syndrome · France.

Enrollment
27th of 40
86 · median 169
Started
2016
with 2 others
Phase 2
14 of 58
2 open now
Registered
8th of 58
by date
Lead sponsor
2 of 58
GlaxoSmithKline

Among the 58 studies in Sjogren's Syndrome with a site in France, this one is the 27th largest by enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2016, is one of 14 in phase 2, and was the 8th registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

18 of the 58 studies in Sjogren's Syndrome with a site in France are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Sjogren's Syndrome with a site in France, or all of them as a file.
02

Study summary

This study is a multi-national, multi-center, double-blind (sponsor open), randomized, placebo-controlled trial in subjects with active primary Sjögren's syndrome designed to understand the safety and tolerability profile of belimumab/ rituximab co-administration and of belimumab monotherapy; and to evaluate whether either co-administration therapy or belimumab monotherapy has a substantive effect on disease activity.

This study will consist screening period, double blind treatment period, a general follow-up period and individualized follow-up period. Approximately 70 subjects will be recruited into the study initially. At Day 0, subjects will be randomized 1:2:2:2 to one of the four treatment arms placebo arm, belimumab monotherapy arm, co-administration therapy arm and rituximab monotherapy arm. Once a sufficient number of subjects have completed the Week 24, interim analyses and sample size re-estimation will be conducted. The total number of subjects randomized may increase following sample size re-estimation up to a maximum of 120 recruited into the study.

Subjects in all arms will receive investigational product (IP) until Week 52 (completion of the treatment phase). All subjects will enter a 16-week general follow-up period after the Week 52 visit or after discontinuation if a subject discontinues IP and withdraws from the treatment phase visits prior to Week 52.

After completing the general follow-up period, subjects with cluster of differentiation (CD)19+ B-cell levels below the lower limit of normal (or less than 90 percent [%] of baseline, if baseline value was below lower limit of normal [LLN]) will enter an individualized safety follow-up phase and return to the clinic for visits every 12 weeks with monthly calls between visits to evaluate subjects for any serious adverse events (SAEs) related to IP or study participation, fatal SAEs, and designated adverse event of special interests (AESIs) (i.e., infections, malignancies, or depression, suicide/self-injury), and to check concomitant medications.

The total duration of participation of a subject in this study will be approximately up to a maximum of 2 years (i.e., up to Week 104).

03

Conditions studied

  • Sjogren's Syndrome

Browse trials for

Keywords

  • Subcutaneous
  • Rituximab
  • Intravenous
  • Safety
  • Efficacy
  • Sjogren's syndrome
  • Belimumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >=18 years, at the time of signing the .
  • Documented Primary Sjögren's Syndrome by American European Consensus Group criteria including: either anti-Sjogren's-syndrome-related antigen A (SS-A) or anti-Sjogren's-syndrome-related antigen B (SS-B) positive.
  • Baseline unstimulated salivary flow >0.0 mL/min or evidence of glandular reserve function (stimulated baseline salivary flow >0.05 mL/min).
  • Symptomatic oral dryness (>=5/10 on subject completed numeric response scale).
  • Systemically active disease, ESSDAI >=5 points.
  • Male and female subjects; females of child bearing potential are eligible if using effective : Female subject is eligible to participate if she is not pregnant (as confirmed by a negative urine human chorionic gonadotropin [hCG] test), not lactating, and at least one of the following conditions applies:

    1. Non- defined as: Pre-menopausal females with one of the following: Documented tubal ligation, Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion, Hysterectomy, Documented Bilateral Oophorectomy.

      defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone [FSH] and estradiol levels consistent with menopause). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods if they wish to continue their HRT during the study; otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment.

    2. Reproductive potential and agrees to follow one of the options in the GlaxoSmithKline (GSK) Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) requirements from 30 days prior to the first dose of study medication up to Week 68 after Day 0.
  • Ability to understand and comply with the protocol-required procedures and provision of informed consent.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of secondary Sjögren's syndrome.
  • Active life-threatening or organ-threatening complications of Sjogren's-syndrome (SS) disease at the time of screening based on treating physician evaluation including but not restricted to (1) vasculitis with renal, digestive, cardiac, pulmonary or central nervous system (CNS) involvement characterized as severe, (2) active CNS or peripheral nervous system (PNS) involvement requiring high dose , (3) severe renal involvement defined by objective measures, (4) lymphoma.
  • History of major organ transplant (including hematopoietic stem cell transplant).
  • History of within past 5 years (with the exception of adequately treated: [1] cervical carcinoma Stage 1B or less, [2] non-invasive basal cell and squamous cell skin carcinoma).
  • History of infection requiring long term systemic therapy including: (1) history of positive (HIV) serology, (2) positive serology for virus (HCV), (3) positive serology for (HB), defined as: HB surface antigen positive (HBsAg+) OR HB core antibody positive (HBcAb+).
  • Previous serious opportunistic or atypical infections or hospitalization for treatment of infection within 364 days of Day 0 or use of parenteral (intravenous [IV] or intramuscular [IM]) antibacterials, antivirals, anti-fungals, or anti-parasitic agents within 364 days of prior to Day 0.
  • Patients in a severely state.
  • History of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins or monoclonal antibodies.
  • History of significant medical illness (or planned surgical procedure) which in the opinion of the investigator would interfere with the study procedures and / or assessments - including but not limited to immunoglobulin G4 (IgG4) disease or prior head or neck irradiation.
  • Severe heart failure (, Class IV) or other severe, uncontrolled cardiac disease.
  • Tuberculosis (TB), defined as: prior history of TB infection; suspicion of TB infection or current TB infection
  • At risk of suicide, as indicated by a lifetime history of attempted suicide or significant suicidal ideation over the 6 months prior to the screening visit; or, if in the Investigator's judgment, the subject is at risk for a suicide attempt.
  • Neurological findings consistent with Progressive Multifocal Leukoencephalopathy (PML) - not otherwise explained - or confirmed PML.
  • (ECG) showing a abnormality at Screening or showing an average using Bazett's formula (QTcB) or corrected QT using Fridericia's formula (QTcF) interval >=450 milliseconds (msec) (>=480 msec for subjects with a Bundle Branch Block) over 3 consecutive ECGs.
  • (ALT) >2x (ULN) and >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
  • Use of systemic immunosuppressive or immunomodulatory agents including methotrexate, azathioprine, leflunomide, mycophenolate (including mycophenolate mofetil, mycophenolate mofetil hydrochloride, and mycophenolate sodium), mizoribine, calcineurin inhibitors [e.g., tacrolimus, cyclosporine], sirolimus, 6-mercaptopurine, or thalidomide within 60 days prior to Day 0.
  • Have received cyclophosphamide within 180 days prior to Day 0.
  • Have received anti- B lymphocyte stimulator (BLyS), anti-CD 20, anti-CD22 or anti-CD52 or any other B-cell depleting agent within 364 days prior to Day 0.
  • Have received abatacept or any biologic agent within 180 day prior to Day 0 (with exception of denosumab).
  • Have received intravenous immunoglobulin (IVIG) or plasmapheresis within 90 days prior to Day 0.
  • Have received oral steroid >10 milligram (mg) prednisone equivalent/day within 30 days prior to Day 0 or oral steroid >20 mg prednisone equivalent / day for a minimum of two consecutive weeks within 60 days prior to Day 0. Have received parenteral steroid within 60 days prior to Day 0.
  • Have received a within 30 days of Day 0.
  • Current participation in any other interventional trial.
  • Planned blood donation during the treatment and follow up periods of the study.
  • Subjects who are unable or unwilling to administer, or to have a caregiver administer subcutaneous injections.
  • Drug or alcohol abuse or dependence.
  • History of to belimumab and/or rituximab or known to have titers of human anti-mouse antibody or human anti-chimeric antibody or history of hypersensitivity reactions when treated with other diagnostic or therapeutic monoclonal antibodies.
  • Have an IgA deficiency (IgA level \<10 milligram per deciliter [mg/dL]).
  • Any of the following screening laboratory values: White blood cells (WBC) \<2 x 10\^9/L; Neutrophils \<1.5 x 10\^9/Liter (L); Circulating IgG or IgM levels \<lower limit of normal (according to central laboratory range); Aspartate aminotransferase (AST) >2.0 times the upper limit of normal; Alkaline phosphatase (ALP) >1.5 times the upper limit of normal; Bilirubin >1.5 times the upper limit of normal; \<400 cells per cubic millimetre (cells/mm\^3); CD8 count \<150 cells/mm\^3; CD19+ B-lymphocyte counts \<0.1 x 10\^9/L.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
86 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Subjects will receive belimumab placebo weekly subcutaneous injections to Week 52 and rituximab placebo infusions at Weeks 8 and 10.

    Drug: Placebo belimumab · Drug: Placebo rituximab

  • Experimental
    Belimumab monotherapy

    Subjects will receive 200 mg weekly subcutaneous injections of belimumab to Week 52 and placebo rituximab infusions at Weeks 8 and 10.

    Drug: Belimumab · Drug: Placebo rituximab

  • Experimental
    Belimumab and Rituximab co-administration therapy

    Subjects will receive belimumab 200 mg SC weekly for 24 weeks followed by weekly placebo belimumab injections to Week 52 with rituximab 1000 mg intravenously at Weeks 8 and 10.

    Drug: Belimumab · Drug: Rituximab · Drug: Placebo belimumab

  • Active comparator
    Rituximab monotherapy

    Subjects will receive 1000 mg IV rituximab infusions at Weeks 8 and 10 and weekly subcutaneous injections of placebo belimumab to Week 52.

    Drug: Rituximab · Drug: Placebo belimumab

Interventions

  • Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.

  • Rituximab will be provided as a 100 mg concentrated solution for infusion. It is a clear, colorless liquid.

  • DrugPlacebo belimumab

    The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.

  • DrugPlacebo rituximab

    Placebo rituximab will be provided as solution for infusion. It is a clear, colorless liquid.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Serious Adverse Events (SAE) and Non-serious AEs (Non-SAE)

    An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations based on medical or scientific judgment and is associated with liver injury and impaired liver function. Data for number of participants with SAE and non-SAE has been summarized.

    Time frame: Up to Week 68

  2. Number of Participants With Adverse Event of Special Interests (AESIs)

    An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AESIs were Malignant Neoplasms, Post-Administration Systemic Reactions (PASR), All Infections of Special Interest (opportunistic infections, herpes zoster, tuberculosis and sepsis), Depression/suicide/self-injury, Deaths and study specific AESI which includes: severe skin reaction per GlaxoSmithKline (GSK) Adjudication, cardiac disorders, Posterior Reversible Encephalopathy Syndrome (PRES) and Progressive multifocal leukoencephalopathy (PML). Data for number of participants with AESI has been summarized.

    Time frame: Up to Week 68

Secondary outcomes

  1. Change From Baseline in European League Against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) Total Scores Over Time

    The ESSDAI is a physician assessed disease activity index developed by EULAR consortium consisting of twelve different clinically relevant organ specific domains; cutaneous, respiratory, renal, articular, muscular, peripheral nervous system, central nervous system, hematological, glandular, constitutional, lymphadenopathy and biological. Each domain has 3 or 4 possible activity levels (i.e., no, low, moderate, high \[if available\]) using a 4-point scale, ranging from 0 (No activity) to 3 (High activity). Higher score indicates high disease activity. Each domain is assigned a weight between 1 and 6. The Total ESSDAI Scores are obtained by multiplying the level of activity (domain score) by the domain weights, ranges between 0 (no activity) and 123 (highest activity). Higher score indicates more disease activity. Baseline value is the screening visit value (within 35 days prior to Day 0). Change from Baseline was defined as the post-dose visit value minus Baseline value.

    Time frame: Baseline (Screening [within 35 days prior to Day 0]), Week 12, Week 24, Week 36, Week 52 and Week 68

  2. Stimulated Salivary Flow Rate Over Time

    Participants were instructed to chew a piece of paraffin wax for a period of 5 minutes and saliva was collected. The volume of saliva (milliliter) was divided by the duration of the test (minutes) to calculate the stimulated salivary flow rate (milliliter per minute). Baseline value is the screening visit value (within 35 days prior to Day 0).

    Time frame: Baseline (Screening [within 35 days prior to Day 0]), Week 12, Week 24, Week 36, Week 52 and Week 68

  3. Oral Dryness Numeric Response Scale (NRS) Over Time

    Oral dryness was reported by participants on a numeric response scale, ranging from 0 (no dryness) to 10 (maximal dryness), higher score indicates worst imaginable dryness. Baseline value is the screening visit value (within 35 days prior to Day 0).

    Time frame: Baseline (Screening [within 35 days prior to Day 0]), Week 12, Week 24, Week 36, Week 52 and Week 68

  4. Absolute Values for B-cells (Cluster of Differentiation 20 [CD20]) Within Salivary Gland Biopsy at Week 24

    Minor salivary gland biopsies were taken for histological analysis to quantify CD20 B Cells.

    Time frame: At Week 24

07

Results

Posted Jun 9, 2021

Participant flow

This study was conducted in 10 countries across 31 centers. Participants were randomized to receive one of the four treatments; Placebo, Belimumab + Rituximab Co-administration therapy, Belimumab Monotherapy or Rituximab Monotherapy.

Treatment Period (Up to Week 52)
Participant flow — Treatment Period (Up to Week 52)
MilestonePlaceboBelimumab + Rituximab Co-administration TherapyBelimumab MonotherapyRituximab Monotherapy
Started13242425
Completed9171917
Not completed4758
Withdrew: Adverse event1522
Withdrew: Withdrawal by subject1125
Withdrew: Lack of efficacy1100
Withdrew: Physician decision1001
Withdrew: Reached stopping criteria0010
General Follow-up (GFU) (Up to Week 68)
Participant flow — General Follow-up (GFU) (Up to Week 68)
MilestonePlaceboBelimumab + Rituximab Co-administration TherapyBelimumab MonotherapyRituximab Monotherapy
Started9171917
Completed8171916
Not completed1001
Withdrew: Lost to follow-up1001

Outcome measures

PrimaryNumber of Participants With Serious Adverse Events (SAE) and Non-serious AEs (Non-SAE)

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations based on medical or scientific judgment and is associated with liver injury and impaired liver function. Data for number of participants with SAE and non-SAE has been summarized.

Time frame:
Up to Week 68
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAE) and Non-serious AEs (Non-SAE)
ParticipantsPlaceboBelimumab + Rituximab Co-administration TherapyBelimumab MonotherapyRituximab Monotherapy
Any SAE0324
Any non-SAE12242317
PrimaryNumber of Participants With Adverse Event of Special Interests (AESIs)

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AESIs were Malignant Neoplasms, Post-Administration Systemic Reactions (PASR), All Infections of Special Interest (opportunistic infections, herpes zoster, tuberculosis and sepsis), Depression/suicide/self-injury, Deaths and study specific AESI which includes: severe skin reaction per GlaxoSmithKline (GSK) Adjudication, cardiac disorders, Posterior Reversible Encephalopathy Syndrome (PRES) and Progressive multifocal leukoencephalopathy (PML). Data for number of participants with AESI has been summarized.

Time frame:
Up to Week 68
Reported as:
Count of participants · Participants
Number of Participants With Adverse Event of Special Interests (AESIs)
ParticipantsPlaceboBelimumab + Rituximab Co-administration TherapyBelimumab MonotherapyRituximab Monotherapy
Malignant Neoplasms0001
PASR4235
All Infections of Special Interest2132
Depression/Suicide/Self-injury0351
Deaths0100
Severe Skin Reactions0000
Cardiac Disorders0101
PRES0000
PML0000
SecondaryChange From Baseline in European League Against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) Total Scores Over Time

The ESSDAI is a physician assessed disease activity index developed by EULAR consortium consisting of twelve different clinically relevant organ specific domains; cutaneous, respiratory, renal, articular, muscular, peripheral nervous system, central nervous system, hematological, glandular, constitutional, lymphadenopathy and biological. Each domain has 3 or 4 possible activity levels (i.e., no, low, moderate, high \[if available\]) using a 4-point scale, ranging from 0 (No activity) to 3 (High activity). Higher score indicates high disease activity. Each domain is assigned a weight between 1 and 6. The Total ESSDAI Scores are obtained by multiplying the level of activity (domain score) by the domain weights, ranges between 0 (no activity) and 123 (highest activity). Higher score indicates more disease activity. Baseline value is the screening visit value (within 35 days prior to Day 0). Change from Baseline was defined as the post-dose visit value minus Baseline value.

Time frame:
Baseline (Screening [within 35 days prior to Day 0]), Week 12, Week 24, Week 36, Week 52 and Week 68
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in European League Against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) Total Scores Over Time
Scores on a scalePlaceboBelimumab + Rituximab Co-administration TherapyBelimumab MonotherapyRituximab Monotherapy
Week 12; n=8, 17, 19 ,15-2.00 ± 1.449-4.85 ± 0.996-3.87 ± 0.949-4.22 ± 1.048
Week 24; n=8, 17, 19 ,16-2.87 ± 1.324-5.32 ± 0.911-3.87 ± 0.869-5.25 ± 0.940
Week 36; n=8, 17, 19 ,16-3.12 ± 1.520-4.09 ± 1.045-4.23 ± 0.995-4.94 ± 1.079
Week 52;n=8, 17, 19 ,16-2.87 ± 1.294-5.67 ± 0.890-4.76 ± 0.850-4.32 ± 0.919
Week 68;n=8, 17, 19 ,16-1.75 ± 1.400-5.73 ± 0.962-3.87 ± 0.918-4.38 ± 0.994
Statistical analysis
  • Placebo vs Belimumab + Rituximab Co-administration Therapy · Least square (ls) mean difference: -2.86 · 95% CI -6.38 to 0.67Week 12. Analysis was performed using mixed effects repeated measures model, with Baseline, treatment, visit and interactions of visit with treatment as fixed effects and participant as a random effect.
  • Belimumab + Rituximab Co-administration Therapy vs Belimumab Monotherapy · Ls mean difference: -0.99 · 95% CI -3.75 to 1.78Week 12. Analysis was performed using mixed effects repeated measures model, with Baseline, treatment, visit and interactions of visit with treatment as fixed effects and participant as a random effect.
  • Belimumab + Rituximab Co-administration Therapy vs Rituximab Monotherapy · Ls mean difference: -0.63 · 95% CI -3.52 to 2.26Week 12. Analysis was performed using mixed effects repeated measures model, with Baseline, treatment, visit and interactions of visit with treatment as fixed effects and participant as a random effect.
  • Placebo vs Belimumab Monotherapy · Ls mean difference: -1.87 · 95% CI -5.34 to 1.60Week 12. Analysis was performed using mixed effects repeated measures model, with Baseline, treatment, visit and interactions of visit with treatment as fixed effects and participant as a random effect.
  • Belimumab Monotherapy vs Rituximab Monotherapy · Ls mean difference: 0.35 · 95% CI -2.50 to 3.20Week 12. Analysis was performed using mixed effects repeated measures model, with Baseline, treatment, visit and interactions of visit with treatment as fixed effects and participant as a random effect.
  • Placebo vs Belimumab + Rituximab Co-administration Therapy · Ls mean difference: -2.45 · 95% CI -5.67 to 0.77Week 24. Analysis was performed using mixed effects repeated measures model, with Baseline, treatment, visit and interactions of visit with treatment as fixed effects and participant as a random effect.
  • Belimumab + Rituximab Co-administration Therapy vs Belimumab Monotherapy · Ls mean difference: -1.46 · 95% CI -3.99 to 1.08Week 24. Analysis was performed using mixed effects repeated measures model, with Baseline, treatment, visit and interactions of visit with treatment as fixed effects and participant as a random effect.
  • Belimumab + Rituximab Co-administration Therapy vs Rituximab Monotherapy · Ls mean difference: -0.07 · 95% CI -2.68 to 2.55Week 24. Analysis was performed using mixed effects repeated measures model, with Baseline, treatment, visit and interactions of visit with treatment as fixed effects and participant as a random effect.
  • Placebo vs Belimumab Monotherapy · Ls mean difference: -1.00 · 95% CI -4.17 to 2.18Week 24. Analysis was performed using mixed effects repeated measures model, with Baseline, treatment, visit and interactions of visit with treatment as fixed effects and participant as a random effect.
  • Belimumab Monotherapy vs Rituximab Monotherapy · Ls mean difference: 1.39 · 95% CI -1.20 to 3.97Week 24. Analysis was performed using mixed effects repeated measures model, with Baseline, treatment, visit and interactions of visit with treatment as fixed effects and participant as a random effect.
  • Placebo vs Belimumab + Rituximab Co-administration Therapy · Ls mean difference: -0.97 · 95% CI -4.66 to 2.73Week 36. Analysis was performed using mixed effects repeated measures model, with Baseline, treatment, visit and interactions of visit with treatment as fixed effects and participant as a random effect.
  • Belimumab + Rituximab Co-administration Therapy vs Belimumab Monotherapy · Ls mean difference: 0.15 · 95% CI -2.76 to 3.05Week 36. Analysis was performed using mixed effects repeated measures model, with Baseline, treatment, visit and interactions of visit with treatment as fixed effects and participant as a random effect.
  • Belimumab + Rituximab Co-administration Therapy vs Rituximab Monotherapy · Ls mean difference: 0.85 · 95% CI -2.15 to 3.86Week 36. Analysis was performed using mixed effects repeated measures model, with Baseline, treatment, visit and interactions of visit with treatment as fixed effects and participant as a random effect.
  • Placebo vs Belimumab Monotherapy · Ls mean difference: -1.11 · 95% CI -4.76 to 2.53Week 36. Analysis was performed using mixed effects repeated measures model, with Baseline, treatment, visit and interactions of visit with treatment as fixed effects and participant as a random effect.
  • Belimumab Monotherapy vs Rituximab Monotherapy · Ls mean difference: 0.71 · 95% CI -2.25 to 3.66Week 36. Analysis was performed using mixed effects repeated measures model, with Baseline, treatment, visit and interactions of visit with treatment as fixed effects and participant as a random effect.
  • Placebo vs Belimumab + Rituximab Co-administration Therapy · Ls mean difference: -2.80 · 95% CI -5.95 to 0.34Week 52. Analysis was performed using mixed effects repeated measures model, with Baseline, treatment, visit and interactions of visit with treatment as fixed effects and participant as a random effect.
  • Belimumab + Rituximab Co-administration Therapy vs Belimumab Monotherapy · Ls mean difference: -0.91 · 95% CI -3.39 to 1.56Week 52. Analysis was performed using mixed effects repeated measures model, with Baseline, treatment, visit and interactions of visit with treatment as fixed effects and participant as a random effect.
  • Belimumab + Rituximab Co-administration Therapy vs Rituximab Monotherapy · Ls mean difference: -1.36 · 95% CI -3.91 to 1.20Week 52. Analysis was performed using mixed effects repeated measures model, with Baseline, treatment, visit and interactions of visit with treatment as fixed effects and participant as a random effect.
  • Placebo vs Belimumab Monotherapy · Ls mean difference: -1.89 · 95% CI -4.99 to 1.21Week 52. Analysis was performed using mixed effects repeated measures model, with Baseline, treatment, visit and interactions of visit with treatment as fixed effects and participant as a random effect.
  • Belimumab Monotherapy vs Rituximab Monotherapy · Ls mean difference: -0.44 · 95% CI -2.97 to 2.08Week 52. Analysis was performed using mixed effects repeated measures model, with Baseline, treatment, visit and interactions of visit with treatment as fixed effects and participant as a random effect.
  • Placebo vs Belimumab + Rituximab Co-administration Therapy · Ls mean difference: -3.99 · 95% CI -7.39 to -0.58Week 68. Analysis was performed using mixed effects repeated measures model, with Baseline, treatment, visit and interactions of visit with treatment as fixed effects and participant as a random effect.
  • Belimumab + Rituximab Co-administration Therapy vs Belimumab Monotherapy · Ls mean difference: -1.87 · 95% CI -4.54 to 0.81Week 68. Analysis was performed using mixed effects repeated measures model, with Baseline, treatment, visit and interactions of visit with treatment as fixed effects and participant as a random effect.
  • Belimumab + Rituximab Co-administration Therapy vs Rituximab Monotherapy · Ls mean difference: -1.35 · 95% CI -4.12 to 1.41Week 68. Analysis was performed using mixed effects repeated measures model, with Baseline, treatment, visit and interactions of visit with treatment as fixed effects and participant as a random effect.
  • Placebo vs Belimumab Monotherapy · Ls mean difference: -2.12 · 95% CI -5.47 to 1.23Week 68. Analysis was performed using mixed effects repeated measures model, with Baseline, treatment, visit and interactions of visit with treatment as fixed effects and participant as a random effect.
  • Belimumab Monotherapy vs Rituximab Monotherapy · Ls mean difference: 0.51 · 95% CI -2.21 to 3.24Week 68. Analysis was performed using mixed effects repeated measures model, with Baseline, treatment, visit and interactions of visit with treatment as fixed effects and participant as a random effect.
SecondaryStimulated Salivary Flow Rate Over Time

Participants were instructed to chew a piece of paraffin wax for a period of 5 minutes and saliva was collected. The volume of saliva (milliliter) was divided by the duration of the test (minutes) to calculate the stimulated salivary flow rate (milliliter per minute). Baseline value is the screening visit value (within 35 days prior to Day 0).

Time frame:
Baseline (Screening [within 35 days prior to Day 0]), Week 12, Week 24, Week 36, Week 52 and Week 68
Reported as:
Mean · Milliliter per minute
Stimulated Salivary Flow Rate Over Time
Milliliter per minutePlaceboBelimumab + Rituximab Co-administration TherapyBelimumab MonotherapyRituximab Monotherapy
Baseline (Screening); n=8, 17, 19 ,160.470 ± 0.24700.714 ± 0.62940.425 ± 0.32920.618 ± 0.6211
Week 12; n=8, 17, 19 ,160.486 ± 0.20450.754 ± 0.83420.493 ± 0.37330.581 ± 0.5265
Week 24; n=8, 17, 19 ,160.554 ± 0.30540.784 ± 0.79000.454 ± 0.41050.724 ± 0.8901
Week 36; n=8, 17, 19 ,150.404 ± 0.24971.039 ± 1.10270.506 ± 0.42610.689 ± 0.5907
Week 52; n=8, 17, 19 ,160.531 ± 0.37820.999 ± 1.14570.582 ± 0.60840.693 ± 0.7813
Week 68; n=8, 17, 19 ,150.361 ± 0.16280.879 ± 0.81670.517 ± 0.44990.733 ± 0.7850
SecondaryOral Dryness Numeric Response Scale (NRS) Over Time

Oral dryness was reported by participants on a numeric response scale, ranging from 0 (no dryness) to 10 (maximal dryness), higher score indicates worst imaginable dryness. Baseline value is the screening visit value (within 35 days prior to Day 0).

Time frame:
Baseline (Screening [within 35 days prior to Day 0]), Week 12, Week 24, Week 36, Week 52 and Week 68
Reported as:
Mean · Scores on a scale
Oral Dryness Numeric Response Scale (NRS) Over Time
Scores on a scalePlaceboBelimumab + Rituximab Co-administration TherapyBelimumab MonotherapyRituximab Monotherapy
Baseline (Screening); n= 8, 17, 19, 167.6 ± 1.517.4 ± 1.467.2 ± 2.147.3 ± 1.91
Week 12; n=8, 17, 19, 166.1 ± 2.595.7 ± 1.966.9 ± 2.325.1 ± 2.77
Week 24; n=8, 17, 19, 155.8 ± 2.385.3 ± 1.836.8 ± 2.515.6 ± 2.72
Week 36; n=8, 17, 19, 165.8 ± 2.765.9 ± 2.266.6 ± 2.196.2 ± 2.51
Week 52; n=8, 17, 19, 165.6 ± 2.135.7 ± 1.927.0 ± 2.406.3 ± 2.32
Week 68; n=8, 17, 19, 166.6 ± 2.266.1 ± 2.636.9 ± 2.346.1 ± 2.62
SecondaryAbsolute Values for B-cells (Cluster of Differentiation 20 [CD20]) Within Salivary Gland Biopsy at Week 24

Minor salivary gland biopsies were taken for histological analysis to quantify CD20 B Cells.

Time frame:
At Week 24
Reported as:
Mean · Cells per millimeter square
Absolute Values for B-cells (Cluster of Differentiation 20 [CD20]) Within Salivary Gland Biopsy at Week 24
Cells per millimeter squarePlaceboBelimumab + Rituximab Co-administration TherapyBelimumab MonotherapyRituximab Monotherapy
Absolute Values for B-cells (Cluster of Differentiation 20 [CD20]) Within Salivary Gland Biopsy at Week 24380.21719 ± 569.9081028.65550 ± 20.199794396.86058 ± 781.245844650.76069 ± 1311.360352

Adverse events

Collected over Serious adverse events (SAEs) and non-SAEs were collected up to Week 68.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/13 (0%)0/13 (0%)12/13 (92.3%)
Belimumab + Rituximab Co-administration Therapy1/24 (4.2%)3/24 (12.5%)24/24 (100%)
Belimumab Monotherapy0/24 (0%)2/24 (8.3%)23/24 (95.8%)
Rituximab Monotherapy0/25 (0%)4/25 (16%)17/25 (68%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPlaceboBelimumab + Rituximab Co-administration TherapyBelimumab MonotherapyRituximab Monotherapy
Enterocolitis infectiousInfections and infestations0/131/240/240/25
PneumoniaInfections and infestations0/130/241/240/25
PyelonephritisInfections and infestations0/131/240/240/25
Atrial flutterCardiac disorders0/131/240/240/25
Sjogren's syndromeMusculoskeletal and connective tissue disorders0/130/241/240/25
AspirationRespiratory, thoracic and mediastinal disorders0/131/240/240/25
BronchitisInfections and infestations0/130/240/241/25
Ophthalmic herpes zosterInfections and infestations0/130/240/241/25
Cardiac failure acuteCardiac disorders0/130/240/241/25
NeutropeniaBlood and lymphatic system disorders0/130/240/241/25
Most frequent other events
Showing 10 of 27
Most frequent other events
EventPlaceboBelimumab + Rituximab Co-administration TherapyBelimumab MonotherapyRituximab Monotherapy
NasopharyngitisInfections and infestations4/138/246/243/25
PyrexiaGeneral disorders4/133/242/242/25
ArthralgiaMusculoskeletal and connective tissue disorders2/137/247/245/25
FatigueGeneral disorders3/136/242/242/25
DizzinessNervous system disorders0/132/246/242/25
HeadacheNervous system disorders2/135/244/246/25
Urinary tract infectionInfections and infestations3/135/243/242/25
InfluenzaInfections and infestations3/130/244/241/25
DiarrhoeaGastrointestinal disorders3/133/243/241/25
RashSkin and subcutaneous tissue disorders3/133/241/241/25

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboBelimumab + Rituximab Co-administration TherapyBelimumab MonotherapyRituximab MonotherapyTotal
Mean52.7 ± 12.6745.1 ± 10.9352.0 ± 11.4955.2 ± 15.0751.1 ± 13.06
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBelimumab + Rituximab Co-administration TherapyBelimumab MonotherapyRituximab MonotherapyTotal
Female1322222380
Male02226
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboBelimumab + Rituximab Co-administration TherapyBelimumab MonotherapyRituximab MonotherapyTotal
African American/African Heritage12216
American Indian or Alaskan Native00011
Asian - East Asian Heritage01124
White - Arabic/North African Heritage02305
White-White/Caucasian/European Heritage1218182169
African American/African Heritage and Asian Heritage01001
08

Study locations

36 sites
  • GSK Investigational Site
    Buenos Aires, C1111AL, Argentina
  • GSK Investigational Site
    Cordoba, 5000, Argentina
  • GSK Investigational Site
    Toronto, Ontario M5T 2S8, Canada
  • GSK Investigational Site
    Trois-Rivieres, Quebec G8Z 1Y2, Canada
  • GSK Investigational Site
    Bordeaux, 33000, France
  • GSK Investigational Site
    Le Kremlin-Bicêtre, 94275, France
  • GSK Investigational Site
    Lille Cedex, 59037, France
  • GSK Investigational Site
    Paris cedex 10, 75475, France
  • GSK Investigational Site
    Paris cedex 13, 75651, France
  • GSK Investigational Site
    Paris, 75012, France
  • GSK Investigational Site
    Paris, 75013, France
  • GSK Investigational Site
    Paris, 75014, France
  • GSK Investigational Site
    Strasbourg, 67098, France
  • GSK Investigational Site
    Tuebingen, Baden-Wuerttemberg 72076, Germany
  • GSK Investigational Site
    Mainz, Rheinland-Pfalz 55131, Germany
  • GSK Investigational Site
    Bad Abbach, 93077, Germany
  • GSK Investigational Site
    Berlin, 10117, Germany
  • GSK Investigational Site
    Hamburg, 22763, Germany
  • GSK Investigational Site
    Udine, Friuli-Venezia-Giulia 33100, Italy
  • GSK Investigational Site
    Pisa, Toscana 56126, Italy
  • GSK Investigational Site
    Perugia, Umbria 06122, Italy
  • GSK Investigational Site
    Brescia, 25123, Italy
  • GSK Investigational Site
    Padova, 35128, Italy
  • GSK Investigational Site
    Amsterdam, 1081 HZ, Netherlands
  • GSK Investigational Site
    Rotterdam, 3015 CE, Netherlands
  • GSK Investigational Site
    Oslo, 0372, Norway
  • GSK Investigational Site
    Barcelona, 08034, Spain
  • GSK Investigational Site
    L'Hospitalet de Llobregat, 08907, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Madrid, 28050, Spain
  • GSK Investigational Site
    Malmö, SE-205 02, Sweden
  • GSK Investigational Site
    Stockholm, SE-141 86, Sweden
  • GSK Investigational Site
    Swindon, Wiltshire SN3 6BB, United Kingdom
  • GSK Investigational Site
    Edgbaston, B15 2GW, United Kingdom
  • GSK Investigational Site
    London, E1 4DG, United Kingdom
  • GSK Investigational Site
    Newcastle-upon-Tyne, NE1 4LP, United Kingdom
09

References and documents

Publications

  • Raymond K, Maher S, Saucier CD, O'Connor M, Yarlas A, Kosinski M, Chen WH, Gairy K. Validation of the PROFAD-SSI-SF in Patients with Primary Sjogren's Syndrome with Organ Involvement: Results of Qualitative Interviews and Psychometric Analyses. Rheumatol Ther. 2023 Feb;10(1):95-115. doi: 10.1007/s40744-022-00493-2. Epub 2022 Oct 13. PubMed 36227531 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2016 to primary completion in Jun 2020, 52 months.

Results were first posted in Jun 2021, 11 months after primary completion.

Of 26 phase 2 interventional studies under Sjogren's Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's 52 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2015
First posted
Dec 16, 2015
StartActual
Feb 17, 2016
Primary completionActual
Jun 23, 2020
CompletionActual
Jun 23, 2020
Results first posted
Jun 9, 2021
Last update
Jun 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02631538
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 16, 2015
Start date
Feb 17, 2016
Primary completion
Jun 23, 2020
Completion
Jun 23, 2020
Results posted
Jun 9, 2021
Last update
Jun 9, 2021

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Belimumab · Rituximab

Start the discussion